The efficacy of Semax in the treatment of patients at different stages of ischemic stroke
E I Gusev, M Yu Martynov, E V Kostenko, L V Petrova, S N Bobyreva · 2018 · Zh Nevrol Psikhiatr Im S S Korsakova. 118(3 Vyp 2):61–68
What does this source report?
The report links treatment and rehabilitation timing to plasma BDNF and functional outcomes.
- Population and setting
- 110 stroke patients; early/late rehabilitation groups with and without Semax
- Evidence type
- Human comparative study
- Preparation
- Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted
- Source language
- See original publication; indexed English metadata
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Randomization and blinding are not established by the abstract.
- BDNF association does not prove mediation; rehabilitation timing is a separate influence.
- Disease-specific findings do not establish healthy-person enhancement.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: E I Gusev, M Yu Martynov, E V Kostenko, L V Petrova, S N Bobyreva. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke Zh Nevrol Psikhiatr Im S S Korsakova. 118(3 Vyp 2):61–68 2018.
Molekul research summary: https://molekul.io/research/ss-29798983. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry